Quantification of frequent-hitter behavior based on historical high-throughput screening data.

AIM We mine historical high-throughput data to identify and characterize 'frequent hitters', hits that are potentially false-positive results. BACKGROUND A key problem in the field of high-throughput screening (HTS) is recognition of frequent hitters, which are false-positive or otherwise anomalous compounds that tend to crop up across many screens. Follow-up of such compounds constitutes a waste of resource and decreases efficiency. METHODOLOGY We describe a systematic retrospective approach to identify anomalous hitter behavior using historical screening data. We take into account the uncertainty that arises if not enough screen data are available and extend implementation to target and technology classes. CONCLUSION Use of the descriptor in analyzing high-throughput screen results frees up resource for follow-up of more likely true hits in the downstream hit-deconvolution cascade, thereby increasing efficiency of screen delivery. Although effective, historical data bias can affect the annotation, and we exemplify cases where this happened.

[1]  Niu Huang,et al.  Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors. , 2012, Journal of medicinal chemistry.

[2]  Francesco Naso,et al.  The Betti base: the awakening of a sleeping beauty , 2010 .

[3]  Catherine Bardelle,et al.  Development of a High-Content High-Throughput Screening Assay for the Discovery of ATM Signaling Inhibitors , 2012, Journal of biomolecular screening.

[4]  Adrian Whitty,et al.  Growing PAINS in academic drug discovery. , 2011, Future medicinal chemistry.

[5]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[6]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[7]  Ramin Miri,et al.  2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents. , 2013, European journal of medicinal chemistry.

[8]  David Beer,et al.  Efficient Elimination of Nonstoichiometric Enzyme Inhibitors from HTS Hit Lists , 2009, Journal of biomolecular screening.

[9]  T. Tomašič,et al.  Rhodanine as a privileged scaffold in drug discovery. , 2009, Current medicinal chemistry.

[10]  Ian A. Watson,et al.  Rules for identifying potentially reactive or promiscuous compounds. , 2012, Journal of medicinal chemistry.

[11]  W. Patrick Walters,et al.  A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.

[12]  Wolfgang Guba,et al.  Development of a virtual screening method for identification of "frequent hitters" in compound libraries. , 2002, Journal of medicinal chemistry.

[13]  Dirk Strumberg,et al.  Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. , 2005, Drugs of today.

[14]  Ákos Tarcsay,et al.  Contributions of molecular properties to drug promiscuity. , 2013, Journal of medicinal chemistry.

[15]  Christopher P Austin,et al.  Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. , 2010, Journal of medicinal chemistry.

[16]  Lorenz M Mayr,et al.  The Future of High-Throughput Screening , 2008, Journal of biomolecular screening.

[17]  J. Baell.  Observations on screening-based research and some concerning trends in the literature. , 2010, Future medicinal chemistry.

[18]  Thomas Mendgen,et al.  Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. , 2012, Journal of medicinal chemistry.

[19]  Pierre Bruneau,et al.  Search for Predictive Generic Model of Aqueous Solubility Using Bayesian Neural Nets , 2001, J. Chem. Inf. Comput. Sci..

[20]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[21]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[22]  Pierre Bruneau,et al.  logD7.4 Modeling Using Bayesian Regularized Neural Networks. Assessment and Correction of the Errors of Prediction , 2006, J. Chem. Inf. Model..

[23]  Yi Li,et al.  Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening. , 2009, Bioorganic & Medicinal Chemistry Letters.

[24]  James Inglese,et al.  Apparent activity in high-throughput screening: origins of compound-dependent assay interference. , 2010, Current opinion in chemical biology.

[25]  K. Jetter,et al.  Principles and applications of wavelet transformation to chemometrics , 2000 .

[26]  Lorenz M Mayr,et al.  Novel trends in high-throughput screening. , 2009, Current opinion in pharmacology.

[27]  Maria F. Sassano,et al.  Colloidal Aggregation Causes Inhibition of G Protein-Coupled Receptors , 2013, Journal of medicinal chemistry.

[28]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[29]  Peter Wipf,et al.  Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. , 2008, Assay and drug development technologies.